Nivolumab + Relatlimab FDC clinical trials

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.